ArticleCancer medicine2025

Real-World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.

Jingze Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.